

Philippe Saiag

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5506467/publications.pdf>

Version: 2024-02-01

182
papers

9,134
citations

53794

45
h-index

45317

90
g-index

306
all docs

306
docs citations

306
times ranked

9708
citing authors

#	ARTICLE	IF	CITATIONS
1	Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 863-873.	10.7	561
2	Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 1118-1125.	1.6	439
3	Is Dermoscopy (Epiluminescence Microscopy) Useful for the Diagnosis of Melanoma?. <i>Archives of Dermatology</i> , 2001, 137, 1343-50.	1.4	418
4	Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , 2015, 51, 1989-2007.	2.8	404
5	Toxic epidermal necrolysis (Lyell syndrome). <i>Journal of the American Academy of Dermatology</i> , 1990, 23, 1039-1058.	1.2	401
6	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline â€“ Update 2016. <i>European Journal of Cancer</i> , 2016, 63, 201-217.	2.8	330
7	Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , 2015, 51, 2396-2403.	2.8	320
8	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 643-654.	10.7	224
9	Psoriatic fibroblasts induce hyperproliferation of normal keratinocytes in a skin equivalent model in vitro. <i>Science</i> , 1985, 230, 669-672.	12.6	208
10	A Comparison of Two Regimens of Topical Corticosteroids in the Treatment of Patients with Bullous Pemphigoid: A Multicenter Randomized Study. <i>Journal of Investigative Dermatology</i> , 2009, 129, 1681-1687.	0.7	207
11	Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. <i>Lancet Haematology</i> , the, 2019, 6, e48-e57.	4.6	195
12	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. <i>European Journal of Cancer</i> , 2020, 128, 83-102.	2.8	181
13	Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. <i>Journal of the American Academy of Dermatology</i> , 1992, 26, 567-574.	1.2	166
14	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment â€“ Update 2019. <i>European Journal of Cancer</i> , 2020, 126, 159-177.	2.8	154
15	GLI2-Mediated Melanoma Invasion and Metastasis. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1148-1159.	6.3	149
16	Detection of BRAF p.V600E Mutations in Melanomas. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 94-100.	2.8	144
17	Prediction of Survival for Patients With Bullous Pemphigoid. <i>Archives of Dermatology</i> , 2005, 141, 691-8.	1.4	141
18	Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. <i>British Journal of Dermatology</i> , 2013, 169, 579-586.	1.5	141

#	ARTICLE	IF	CITATIONS
19	Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. <i>Blood</i> , 2004, 103, 3662-3668.	1.4	139
20	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics “ Update 2019. <i>European Journal of Cancer</i> , 2020, 126, 141-158.	2.8	133
21	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. <i>European Journal of Cancer</i> , 2020, 128, 60-82.	2.8	131
22	Ultrasonography or palpation for detection of melanoma nodal invasion: a meta-analysis. <i>Lancet Oncology</i> , The, 2004, 5, 673-680.	10.7	120
23	Efficacy of Mohs Micrographic Surgery for the Treatment of Dermatofibrosarcoma Protuberans. <i>Archives of Dermatology</i> , 2012, 148, 1055.	1.4	119
24	Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , 2015, 51, 2604-2608.	2.8	109
25	Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. <i>Aids</i> , 2000, 14, 987-993.	2.2	107
26	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. <i>European Journal of Cancer</i> , 2022, 170, 236-255.	2.8	102
27	Prognostic Value of BRAF V600 Mutations in Melanoma Patients After Resection of Metastatic Lymph Nodes. <i>Annals of Surgical Oncology</i> , 2012, 19, 4314-4321.	1.5	91
28	A new method for studying epidermalization in vitro. <i>British Journal of Dermatology</i> , 1986, 114, 91-101.	1.5	90
29	Allele variations in the OCA2 gene (pink-eyed-dilution locus) are associated with genetic susceptibility to melanoma. <i>European Journal of Human Genetics</i> , 2005, 13, 913-920.	2.8	86
30	Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy. <i>New England Journal of Medicine</i> , 2016, 375, 296-297.	27.0	86
31	Improvement of Survival in Patients With Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, in France. <i>JAMA Dermatology</i> , 2014, 150, 535.	4.1	80
32	Clinical and Virologic Characterization of Acyclovir-Resistant Varicella-Zoster Viruses Isolated from 11 Patients with Acquired Immunodeficiency Syndrome. <i>Clinical Infectious Diseases</i> , 2001, 33, 2061-2067.	5.8	77
33	Evolving Pattern of Drug-Induced Toxic Epidermal Necrolysis. <i>Dermatology</i> , 1993, 186, 32-37.	2.1	76
34	MC1R and PTCH Gene Polymorphism in French Patients with Basal Cell Carcinomas. <i>Journal of Investigative Dermatology</i> , 2006, 126, 1510-1517.	0.7	67
35	Variants of the <i>MATP</i> / <i>SLC45A2</i> gene are protective for melanoma in the French population. <i>Human Mutation</i> , 2008, 29, 1154-1160.	2.5	61
36	PTCH mutations and deletions in patients with typical nevoid basal cell carcinoma syndrome and in patients with a suspected genetic predisposition to basal cell carcinoma: a French study. <i>British Journal of Cancer</i> , 2006, 95, 548-553.	6.4	58

#	ARTICLE	IF	CITATIONS
37	Detection of BRAF V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility. Archives of Pathology and Laboratory Medicine, 2014, 138, 71-75.	2.5	57
38	Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients. Oncoimmunology, 2018, 7, e1442166.	4.6	57
39	Failure of warfarin in treatment of calcinosis universalis. American Journal of Medicine, 1988, 84, 795-796.	1.5	54
40	Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline " Update 2022. European Journal of Cancer, 2022, 171, 203-231.	2.8	51
41	Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18-specific binding motif. European Journal of Immunology, 2000, 30, 2281-2289.	2.9	47
42	Lipodystrophy associated with protease inhibitors. British Journal of Dermatology, 2000, 142, 496-500.	1.5	47
43	Ultrasonography Using Simple Diagnostic Criteria vs Palpation for the Detection of Regional Lymph Node Metastases of Melanoma. Archives of Dermatology, 2005, 141, 183-9.	1.4	47
44	Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma. Oncoimmunology, 2017, 6, e1338237.	4.6	47
45	STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network. Journal of Investigative Dermatology, 2018, 138, 58-67.	0.7	47
46	Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance. Annals of Oncology, 2015, 26, 1470-1475.	1.2	46
47	Interest of corrective makeup in the management of patients in dermatology. Clinical, Cosmetic and Investigational Dermatology, 2012, 5, 123.	1.8	45
48	Outdoor sports and risk of ultraviolet radiation-related skin lesions in children: evaluation of risks and prevention. British Journal of Dermatology, 2011, 165, 360-367.	1.5	43
49	Lipschutz's genital ulceration: a manifestation of Epstein-Barr virus primary infection. British Journal of Dermatology, 1996, 135, 663-665.	1.5	38
50	Treatment of early AIDS-related Kaposi's sarcoma with oral all-trans-retinoic acid. Aids, 1998, 12, 2169-2176.	2.2	38
51	Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort. European Journal of Cancer, 2018, 105, 33-40.	2.8	38
52	Vaccinia from recombinant virus expressing HIV genes. Lancet, The, 1991, 337, 1034-1035.	18.7	37
53	One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis. British Journal of Dermatology, 2014, 170, 435-444.	1.5	37
54	Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma. Journal of the American Academy of Dermatology, 2015, 72, 786-793.	1.2	37

#	ARTICLE	IF	CITATIONS
55	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 655-664.	10.7	37
56	Variations of BRAF mutant allele percentage in melanomas. <i>BMC Cancer</i> , 2015, 15, 497.	2.6	36
57	Management of adult patients with cutaneous melanoma without distant metastasis. 2005 update of the French Standards, Options and Recommendations guidelines. Summary report. <i>European Journal of Dermatology</i> , 2007, 17, 325-31.	0.6	36
58	Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma. <i>British Journal of Cancer</i> , 2004, 90, 503-509.	6.4	35
59	Acute Generalized Exanthematous Pustulosis Induced by Hydroxychloroquine. <i>Dermatology</i> , 1996, 193, 70-71.	2.1	33
60	The contribution of high-resolution ultrasonography in preoperatively detecting sentinel-node metastases in melanoma patients. <i>Melanoma Research</i> , 2007, 17, 233-237.	1.2	33
61	Imiquimod 5% cream for external genital or perianal warts in human immunodeficiency virus-positive patients treated with highly active antiretroviral therapy: an open-label, noncomparative study. <i>British Journal of Dermatology</i> , 2009, 161, 904-909.	1.5	33
62	No Correlation between the Molecular Subtype of COL1A1- <i>PDGFB</i> Fusion Gene and the Clinico-Histopathological Features of Dermatofibrosarcoma Protuberans. <i>Journal of Investigative Dermatology</i> , 2010, 130, 904-907.	0.7	33
63	Medical students and sun prevention: knowledge and behaviours in France. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e247-51.	2.4	33
64	Recurrent Erythema Multiforme Unresponsive to Acyclovir Prophylaxis and Responsive to Valacyclovir Continuous Therapy. <i>Archives of Dermatology</i> , 1998, 134, 876-877.	1.4	32
65	Guidelines for the diagnosis and treatment of Merkel cell carcinoma. Cutaneous Oncology Group of the French Society of Dermatology. <i>European Journal of Dermatology</i> , 2012, 22, 375-379.	0.6	31
66	Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study). <i>EclinicalMedicine</i> , 2021, 35, 100844.	7.1	31
67	Treatment of Undifferentiated Vulvar Intraepithelial Neoplasia With 5% Imiquimod Cream. <i>Archives of Dermatology</i> , 2004, 140, 1220-4.	1.4	30
68	Comparison between UV index measurements performed by research-grade and consumer-products instruments. <i>Photochemical and Photobiological Sciences</i> , 2010, 9, 459-463.	2.9	30
69	First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma. <i>British Journal of Cancer</i> , 2016, 114, 1199-1205.	6.4	30
70	A double-blind, randomized study assessing the equivalence of valacyclovir 1000 mg once daily versus 500 mg twice daily in the episodic treatment of recurrent genital herpes. <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 44, 525-531.	3.0	29
71	Neonatal Blue-Light Phototherapy Does Not Increase Nevus Count in 9-Year-Old Children. <i>Pediatrics</i> , 2009, 123, e896-e900.	2.1	27
72	Genes involved in the WNT and vesicular trafficking pathways are associated with melanoma predisposition. <i>International Journal of Cancer</i> , 2015, 136, 2109-2119.	5.1	27

#	ARTICLE	IF	CITATIONS
73	Sensitivity and specificity of BP180 NC16A enzyme-linked immunosorbent assay for the diagnosis of pemphigoid gestationis. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 560-562.	1.2	27
74	Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort. <i>European Journal of Cancer</i> , 2019, 112, 38-46.	2.8	27
75	Validity of satellite measurements used for the monitoring of UV radiation risk on health. <i>Atmospheric Chemistry and Physics</i> , 2011, 11, 13377-13394.	4.9	26
76	A case-control study of cutaneous signs in adult patients with Marfan disease: Diagnostic value of striae. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 290-295.	1.2	24
77	Are sunscreens luxury products?. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, e73-e79.	1.2	24
78	Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT). <i>British Journal of Dermatology</i> , 2014, 170, 425-434.	1.5	24
79	Effect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma. <i>European Journal of Cancer</i> , 2015, 51, 1780-1793.	2.8	24
80	Association Between Endothelin Receptor B Nonsynonymous Variants and Melanoma Risk. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1297-1301.	6.3	22
81	Projected changes in clear-sky erythemal and vitamin D effective UV doses for Europe over the period 2006 to 2100. <i>Photochemical and Photobiological Sciences</i> , 2013, 12, 1053-1064.	2.9	22
82	The evolving field of Dermatocancerology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV and UEMS and EORTC Cutaneous Lymphoma Task Force. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2183-2197.	2.4	22
83	Impact of the French COVID-19 pandemic lockdown on newly diagnosed melanoma delay and severity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	22
84	Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT). <i>Annals of Oncology</i> , 2016, 27, 1947.	1.2	21
85	A LC/MS/MS micro-method for human plasma quantification of vemurafenib. Application to treated melanoma patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 97, 29-32.	2.8	19
86	Variation of mutant allele frequency in NRAS Q61 mutated melanomas. <i>BMC Dermatology</i> , 2017, 17, 9.	2.1	19
87	Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9509-9509.	1.6	19
88	A French CDK4-positive melanoma family with a co-inherited EDNRB mutation. <i>Journal of Dermatological Science</i> , 2007, 46, 61-64.	1.9	18
89	Incomplete efficacy of 5-aminolevulinic acid (5 ALA) photodynamic therapy in the treatment of widespread extramammary Paget's disease. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2012, 28, 53-55.	1.5	18
90	Assessment of tyrosinase variants and skin cancer risk in a large cohort of French subjects. <i>Journal of Dermatological Science</i> , 2011, 64, 127-133.	1.9	17

#	ARTICLE	IF	CITATIONS
91	Evaluation of tourists' UV exposure in Paris. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e294-304.	2.4	16
92	Response to: Mortality Rate of Bullous Pemphigoid in a US Medical Center. <i>Journal of Investigative Dermatology</i> , 2005, 124, 664-665.	0.7	15
93	Sarcoidosis Associated with Leucocytoclastic Vasculitis. <i>Dermatology</i> , 1993, 187, 50-53.	2.1	14
94	Association study of the g.8818A>G polymorphism of the human agouti gene with melanoma risk and pigmentary characteristics in a French population. <i>Journal of Dermatological Science</i> , 2005, 40, 133-136.	1.9	14
95	Efficacy of late concurrent hypofractionated radiotherapy in advanced melanoma patients failing anti-PD-1 monotherapy. <i>International Journal of Cancer</i> , 2020, 147, 1707-1714.	5.1	14
96	Efficacy of imiquimod on external anogenital warts in HIV-infected patients previously treated by highly active antiretroviral therapy. <i>Aids</i> , 2002, 16, 1438-1440.	2.2	14
97	Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data. <i>Annals of Oncology</i> , 2021, 32, 542-551.	1.2	13
98	Regression of sclerodermatous skin lesions in a patient with carcinoid syndrome treated by octreotide. <i>Archives of Dermatology</i> , 1995, 131, 1207-1209.	1.4	13
99	Tacrolimus ointment, an interesting adjunctive therapy for childhood linear IgA bullous dermatosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 364-365.	2.4	12
100	Sentinel Node Status and Immunosuppression: Recurrence Factors in Localized Merkel Cell Carcinoma. <i>Acta Dermato-Venereologica</i> , 2014, 95, 835-40.	1.3	12
101	Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma. <i>European Journal of Dermatology</i> , 2019, 29, 636-640.	0.6	12
102	Quality of life assessment in French patients with metastatic melanoma in real life. <i>Cancer</i> , 2020, 126, 611-618.	4.1	12
103	Frequency and prognostic value of cutaneous molecular residual disease in mycosis fungoides: a prospective multicentre trial of the Cutaneous Lymphoma French Study Group. <i>British Journal of Dermatology</i> , 2015, 173, 1015-1023.	1.5	11
104	Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma. <i>British Journal of Cancer</i> , 2021, 125, 948-954.	6.4	11
105	Narrow resection margins are not associated with mortality or recurrence in patients with Merkel cell carcinoma: A retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 921-929.	1.2	10
106	Escitalopram photo-induced erythroderma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 1015-1017.	2.4	9
107	Bullous DRESS in a patient on strontium ranelate. <i>Clinical and Experimental Dermatology</i> , 2009, 34, e349-e350.	1.3	9
108	Understanding recurrent herpes labialis management and impact on patients' quality of life: the HERPESCOPE study. <i>European Journal of Dermatology</i> , 2013, 23, 491-499.	0.6	9

#	ARTICLE	IF	CITATIONS
109	1121P Factors predicting overall survival (OS) and progression-free survival (PFS) in real-life: Classification and regression tree analysis of a 5-year (5Y) cohort follow-up study of advanced melanoma patients (pts) that have initiated pembrolizumab. <i>Annals of Oncology</i> , 2020, 31, S754-S755.	1.2	9
110	Efficacy, safety and factors associated with disease progression in patients with unresectable (stage) Tj ETQq0 0 0 rgBT /Overlock 10 Tf IIIb study of trametinib in combination with dabrafenib. <i>European Journal of Cancer</i> , 2021, 154, 57-65.	2.8	9
111	Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. <i>Archives of Dermatology</i> , 1995, 131, 669-72.	1.4	9
112	Magnetic resonance imaging in adults presenting with severe acute infectious cellulitis. <i>Archives of Dermatology</i> , 1994, 130, 1150-8.	1.4	9
113	Increase in NRAS mutant allele percentage during metastatic melanoma progression. <i>Experimental Dermatology</i> , 2016, 25, 472-474.	2.9	8
114	Truncating mutations of <i>TP53</i> gene predispose to cutaneous melanoma. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 294-303.	2.8	8
115	Efficacy of hypofractionated radiotherapy (Rx) in melanoma patients who failed anti-PD-1 monotherapy: Assessing the abscopal effect.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9537-9537.	1.6	8
116	Compliance with indoor tanning advertising regulations in France. <i>British Journal of Dermatology</i> , 2011, 164, 880-882.	1.5	7
117	Rapidly growing pancreatic ductal adenocarcinoma in a patient with metastatic melanoma and harbouring CDKN2A germline mutation. <i>Melanoma Research</i> , 2013, 23, 241.	1.2	7
118	Relapsing pneumonitis due to two distinct inhibitors of the MAPK/ERK pathway: report of a case. <i>BMC Cancer</i> , 2015, 15, 732.	2.6	7
119	Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival. <i>JAMA Dermatology</i> , 2019, 155, 673.	4.1	7
120	Development of a core outcome set for cutaneous squamous cell carcinoma trials: identification of core domains and outcomes*. <i>British Journal of Dermatology</i> , 2021, 184, 1113-1122.	1.5	7
121	Melanoma susceptibility and progression: Association study between polymorphisms of the chemokine (CCL2) and chemokine receptors (CX3CR1, CCR5). <i>Journal of Dermatological Science</i> , 2007, 46, 72-76.	1.9	6
122	Reply to the letter to the editor "Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumor response and tolerance" by Funck-Brentano et al.. <i>Annals of Oncology</i> , 2016, 27, 364-365.	1.2	6
123	Histologic predictors of invasion in partially biopsied lentigo maligna melanoma. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1150-1152.	1.2	6
124	Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review. <i>Melanoma Management</i> , 2019, 6, MMT33.	0.5	6
125	Investigation of the RB1-SOX2 axis constitutes a tool for viral status determination and diagnosis in Merkel cell carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 1239-1254.	2.8	6
126	Parents' attitudes related to melanocytic nevus count in children. <i>European Journal of Cancer Prevention</i> , 2010, 19, 472-477.	1.3	5

#	ARTICLE	IF	CITATIONS
127	Interactions between ultraviolet light exposure and DNA repair gene polymorphisms may increase melanoma risk. <i>British Journal of Dermatology</i> , 2010, 162, 891-893.	1.5	5
128	Re: High nevus counts confer a favorable prognosis in melanoma patients by <sc>S</sc> ribero and co-workers, published in the <i><sc>I</sc>nternational <sc>J</sc>ournal of <sc>C</sc>ancer</i>, 2015 (online 21 march 2015). <i>International Journal of Cancer</i> , 2015, 137, 3006-3007.	5.1	5
129	Hyponatremia and MAP&Ekinase inhibitors in malignant melanoma: Frequency, pathophysiological aspects and clinical consequences. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 326-331.	3.3	5
130	Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational study. <i>International Journal of Cancer</i> , 2021, 148, 2789-2798.	5.1	5
131	Differential gradients of efficacy of immunotherapy according to the sun-exposure pattern of the site of occurrence of primary melanoma: A multicenter prospective cohort study (MELBASE).. <i>Journal of Clinical Oncology</i> , 2021, 39, e21545-e21545.	1.6	4
132	Monitoring of plasma concentrations of dabrafenib and trametinib in advanced BRAFV600 melanoma patients. <i>Annales De Dermatologie Et De Venereologie</i> , 2022, 149, 32-38.	1.0	4
133	Which adjuvant treatment for patients with BRAFV600-mutant cutaneous melanoma?. <i>Annales De Dermatologie Et De Venereologie</i> , 2021, 148, 145-155.	1.0	4
134	Phase II multicentric uncontrolled national trial assessing the efficacy of nilotinib in the treatment of advanced melanomas with c-KIT mutation or amplification.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9032-9032.	1.6	4
135	Lasers, dermal fibroblasts and psoriasis. <i>British Journal of Dermatology</i> , 1986, 115, 744-745.	1.5	3
136	Counselling on sun protection, a survey of French paediatricians. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e424-7.	2.4	3
137	Reply to "Clinical and therapeutic implications of <i><sc>BRAF</sc></i> mutation heterogeneity in metastatic melanoma" by Mesbah Ardakani et al.. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 498-500.	3.3	3
138	Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic Melanoma. <i>Cancers</i> , 2021, 13, 3042.	3.7	3
139	Primary medical therapy for BRAFV600E-mutant melanoma brain metastases" is this good enough? " Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e509.	10.7	3
140	Ipilimumab combined with stereotactic radiosurgery in melanoma patients with brain metastases: A multicenter, open label, phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9520-9520.	1.6	3
141	Nonsteroidal anti-inflammatory drugs in cellulitis: a cautionary note. <i>Archives of Dermatology</i> , 1991, 127, 1845-6.	1.4	3
142	Value of fine-needle aspiration in infectious cellulitis. <i>Archives of Dermatology</i> , 1996, 132, 842-3.	1.4	3
143	Focal 3D conformal high-dose hypofractionated radiotherapy for brain metastases. <i>Melanoma Research</i> , 2012, 22, 406-409.	1.2	2
144	On/off dropped head syndrome: A severe adverse event after prolonged treatment with MEK inhibitor. <i>European Journal of Cancer</i> , 2018, 91, 174-176.	2.8	2

#	ARTICLE	IF	CITATIONS
145	Nivolumab to control molecular response in chronic myeloid leukemia. <i>Leukemia Research</i> , 2018, 72, 5-6.	0.8	2
146	Vemurafenib (V) in BRAF V600E metastatic melanoma (mM): Analysis of 507 patients (pts) enrolled in the French temporary authorization for use (ATU).. <i>Journal of Clinical Oncology</i> , 2012, 30, 8591-8591.	1.6	2
147	Immunotherapy-treated melanoma brain metastases within the French national cohort, MelBase.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9556-9556.	1.6	2
148	Impact of simultaneous radiotherapy in melanoma patients treated with pembrolizumab in the French early access program.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9555-9555.	1.6	2
149	An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: A subgroup analysis of patients with brain metastasis. <i>Annals of Oncology</i> , 2019, 30, v542-v543.	1.2	1
150	Second primary cutaneous melanoma in patients with advanced melanoma treated with anti-CTLA-4 monoclonal antibodies. <i>British Journal of Dermatology</i> , 2021, 184, 746-748.	1.5	1
151	Outcomes of elderly treated with pembrolizumab for metastatic melanoma comparing with younger patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21508-e21508.	1.6	1
152	Plasma concentrations of dabrafenib and trametinib (PCD/T) monitoring in advanced BRAFV600-mutant melanoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9541-9541.	1.6	1
153	Does body mass index really predict the response to systemic therapies in metastatic melanoma: A multicenter study from the MelBase French National Cohort?. <i>Journal of Clinical Oncology</i> , 2020, 38, 10031-10031.	1.6	1
154	Sun exposure profile in the French population: Results of the EDIFICE melanoma survey.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1566-1566.	1.6	1
155	Comparison of sun protection modalities in parents and children.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8601-8601.	1.6	1
156	Prognostic value of BRAFV600 mutations in melanoma patients after resection of metastatic lymph nodes.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8540-8540.	1.6	1
157	Discontinuation of anti-PD-1 mAb after complete response in advanced melanoma pts.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21549-e21549.	1.6	1
158	Association of baseline corticosteroid treatment with outcomes for patients (pts) with BRAF-mutant melanoma brain metastases (MBMs) in COMBI-MB treated with dabrafenib and trametinib (DT).. <i>Journal of Clinical Oncology</i> , 2022, 40, e21546-e21546.	1.6	1
159	Pathologies du système nerveux central associées à la maladie de Cowden. <i>Annales De Dermatologie Et De Venereologie</i> , 2004, 131, 1135.	1.0	0
160	Améliorations de la chirurgie micrographique de Mohs sur la base de l'expérience du traitement de 235 carcinomes basocellulaires du visage. <i>Annales De Dermatologie Et De Venereologie</i> , 2005, 132, 606-607.	1.0	0
161	Tacrolimus pommade, une alternative à la corticothérapie locale dans la dermatose à IgA linéaire. <i>Annales De Dermatologie Et De Venereologie</i> , 2007, 134, 608.	1.0	0
162	Projet Réseau cancers cutanés rares K-CUR. <i>Oncologie</i> , 2008, 10, 409-410.	0.7	0

#	ARTICLE	IF	CITATIONS
163	Effectiveness and Safety of Vemurafenib as Monotherapy in Unresectable or Metastatic Melanoma from an Academic Database: Real World Data to Strengthen Evidence for Payer. <i>Value in Health</i> , 2016, 19, A762-A763.	0.3	0
164	Concomitant radiotherapy in melanoma brain metastases using the propensity score matching within the French cohort, MelBase. <i>Annals of Oncology</i> , 2018, 29, viii444-viii445.	1.2	0
165	Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: An open label, non randomized study. <i>Annals of Oncology</i> , 2019, 30, v546.	1.2	0
166	PCN96 COST-EFFECTIVENESS OF TREATMENT SEQUENCES FOR BRAF WILD-TYPE METASTATIC MELANOMA IN REAL LIFE IN FRANCE. <i>Value in Health</i> , 2019, 22, S454-S455.	0.3	0
167	PCN461 CHARACTERIZATION OF THE CARE PATHWAYS OF PATIENTS WITH MERKEL CELL CARCINOMA IN FRANCE. <i>Value in Health</i> , 2019, 22, S526.	0.3	0
168	1080P HORIZON: Final results from a 5-year ambispective study of 705 patients who initiated pembrolizumab for advanced melanoma in the French early access program. <i>Annals of Oncology</i> , 2021, 32, S895.	1.2	0
169	Personal melanoma risk awareness versus intrinsic risk.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9069-9069.	1.6	0
170	Vitamin D level at diagnosis and its variation during follow-up as prognostic factor of cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9057-9057.	1.6	0
171	Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: Impact on tumor response and tolerance.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9016-9016.	1.6	0
172	Frequent allelic imbalance in <i>NRAS</i> mutant melanomas.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9578-9578.	1.6	0
173	Melapred: first susceptibility test to sporadic melanoma in daily dermatological practice.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21056-e21056.	1.6	0
174	HORIZON: A French descriptive cohort of 663 patients treated for melanoma with pembrolizumab with a focus on the mucosal subgroup (n=59).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9563-9563.	1.6	0
175	Elderly patient's tolerance and efficacy for MAP-kinase inhibitors in a French melanoma real-life cohort.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21536-e21536.	1.6	0
176	Horizon: An ambispective study of 663 patients who initiated pembrolizumab for advanced melanoma within the French early access program.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21519-e21519.	1.6	0
177	Immune checkpoint inhibitors and stereotactic radiosurgery (SRS) in melanoma brain metastases.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21523-e21523.	1.6	0
178	Immunological Cytopenias Induced By Anti-Programmed Cell Death (ligand) 1 Antibodies. <i>Blood</i> , 2018, 132, 2412-2412.	1.4	0
179	Progression and hyperprogression after anti-PD1 therapy for unresectable stage III or IV melanoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, e21021-e21021.	1.6	0
180	Pustulotic arthroostitis triggered by echovirus 9?. <i>Journal of Rheumatology</i> , 1993, 20, 1992-3.	2.0	0

#	ARTICLE	IF	CITATIONS
181	Efficacy of immune checkpoint inhibitor (ICI) rechallenge in advanced melanoma patients responders to a first course of ICI: A multicenter, national, retrospective study of the French group of skin cancers (GCC).. Journal of Clinical Oncology, 2022, 40, 9529-9529.	1.6	0
182	Efficacy and tolerance of systemic therapies in metastatic melanoma of unknown primary versus known cutaneous: A multicenter retrospective study from the MelBase French Cohort.. Journal of Clinical Oncology, 2022, 40, 9556-9556.	1.6	0